International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
The Lancet. Oncology.
Times cited: 23
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
- Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. Expert Opinion on Orphan Drugs. 2015 Article GET IT
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study. The Lancet Oncology. 2014 Academic Article GET IT
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Times cited: 69
- Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Academic Article GET IT
- Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
- Re: When you look matters: The effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute. 2008 Information Resource GET IT
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Information Resource GET IT
- Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
- Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Academic Article GET IT
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British journal of haematology. 2004 Academic Article GET IT